Cargando…

A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification

Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Tsuyoshi, Sasaki, Ryo, Nishimura, Tatsuro, Aibe, Yuki, Saeki, Issei, Iwamoto, Takuya, Hidaka, Isao, Takami, Taro, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762126/
https://www.ncbi.nlm.nih.gov/pubmed/31557230
http://dx.doi.org/10.1371/journal.pone.0223153
_version_ 1783454153018703872
author Ishikawa, Tsuyoshi
Sasaki, Ryo
Nishimura, Tatsuro
Aibe, Yuki
Saeki, Issei
Iwamoto, Takuya
Hidaka, Isao
Takami, Taro
Sakaida, Isao
author_facet Ishikawa, Tsuyoshi
Sasaki, Ryo
Nishimura, Tatsuro
Aibe, Yuki
Saeki, Issei
Iwamoto, Takuya
Hidaka, Isao
Takami, Taro
Sakaida, Isao
author_sort Ishikawa, Tsuyoshi
collection PubMed
description Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop a reasonable therapeutic strategy for EV in cirrhosis. From January 2012 to December 2014, 45 patients with cirrhosis and high-risk EV underwent ET, including sclerotherapy and/or ligation. Statistical analyses identified factors associated with the recurrence of EV after ET, and the Kaplan-Meier method determined the cumulative variceal recurrence rates. The 1-, 2-, and 3-year cumulative posttreatment recurrence rates for EV were 13.3%, 29.5%, and 32.2%, respectively. No significant differences were evident between the patients with and without variceal recurrences at 1-year posttreatment. The multivariate regression analyses identified a history of partial splenic embolization (PSE) and the pretreatment Child-Pugh classification as independent predictors of variceal recurrences at 2 years (p < 0.05) and 3 years (p < 0.05) posttreatment. While EV did not recur after ET and splenic artery embolization in cases with Child-Pugh class A, the overall posttreatment variceal recurrence rates were 0% and 66.7% when PSE was performed before and after ET, respectively, in those with Child-Pugh class B or C. Splenic artery embolization significantly reduced the hepatic venous pressure gradient and markedly lowered the Child-Pugh score in 15 patients. Adjunctive PSE and pretreatment Child-Pugh class A could be independently associated with reduced cumulative recurrence rates of EV post-ET. From the perspectives of portal hemodynamics and hepatic function, splenic artery embolization before or after ET could prevent posttreatment variceal recurrence in patients with Child-Pugh class A, and PSE before ET could achieve the long-term eradication of EV following ET in those with Child-Pugh class B or C.
format Online
Article
Text
id pubmed-6762126
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67621262019-10-12 A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification Ishikawa, Tsuyoshi Sasaki, Ryo Nishimura, Tatsuro Aibe, Yuki Saeki, Issei Iwamoto, Takuya Hidaka, Isao Takami, Taro Sakaida, Isao PLoS One Research Article Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop a reasonable therapeutic strategy for EV in cirrhosis. From January 2012 to December 2014, 45 patients with cirrhosis and high-risk EV underwent ET, including sclerotherapy and/or ligation. Statistical analyses identified factors associated with the recurrence of EV after ET, and the Kaplan-Meier method determined the cumulative variceal recurrence rates. The 1-, 2-, and 3-year cumulative posttreatment recurrence rates for EV were 13.3%, 29.5%, and 32.2%, respectively. No significant differences were evident between the patients with and without variceal recurrences at 1-year posttreatment. The multivariate regression analyses identified a history of partial splenic embolization (PSE) and the pretreatment Child-Pugh classification as independent predictors of variceal recurrences at 2 years (p < 0.05) and 3 years (p < 0.05) posttreatment. While EV did not recur after ET and splenic artery embolization in cases with Child-Pugh class A, the overall posttreatment variceal recurrence rates were 0% and 66.7% when PSE was performed before and after ET, respectively, in those with Child-Pugh class B or C. Splenic artery embolization significantly reduced the hepatic venous pressure gradient and markedly lowered the Child-Pugh score in 15 patients. Adjunctive PSE and pretreatment Child-Pugh class A could be independently associated with reduced cumulative recurrence rates of EV post-ET. From the perspectives of portal hemodynamics and hepatic function, splenic artery embolization before or after ET could prevent posttreatment variceal recurrence in patients with Child-Pugh class A, and PSE before ET could achieve the long-term eradication of EV following ET in those with Child-Pugh class B or C. Public Library of Science 2019-09-26 /pmc/articles/PMC6762126/ /pubmed/31557230 http://dx.doi.org/10.1371/journal.pone.0223153 Text en © 2019 Ishikawa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ishikawa, Tsuyoshi
Sasaki, Ryo
Nishimura, Tatsuro
Aibe, Yuki
Saeki, Issei
Iwamoto, Takuya
Hidaka, Isao
Takami, Taro
Sakaida, Isao
A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title_full A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title_fullStr A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title_full_unstemmed A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title_short A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
title_sort novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the child-pugh classification
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762126/
https://www.ncbi.nlm.nih.gov/pubmed/31557230
http://dx.doi.org/10.1371/journal.pone.0223153
work_keys_str_mv AT ishikawatsuyoshi anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT sasakiryo anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT nishimuratatsuro anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT aibeyuki anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT saekiissei anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT iwamototakuya anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT hidakaisao anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT takamitaro anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT sakaidaisao anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT ishikawatsuyoshi noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT sasakiryo noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT nishimuratatsuro noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT aibeyuki noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT saekiissei noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT iwamototakuya noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT hidakaisao noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT takamitaro noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification
AT sakaidaisao noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification